235 research outputs found
Cyberbullying Detection on Social Network Services
Social networks such as Facebook or Twitter promote the communication between people but they also lead to some excessive uses on the Internet such as cyberbullying for malicious users. In addition, the accessibility of the social network also allows cyberbullying to occur at anytime and evoke more harm from other users’ dissemination. This study collects cyberbullying cases in Twitter and attempts to establish an auto-detection model of cyberbullying tweets base on the text, readability, sentiment score, and other user information to predict the tweets with harassment and ridicule cyberbullying tweets. The novelty of this study is using the readability analysis that has not been considered in past studies to reflect the author\u27s education level, age, and social status. Three data mining techniques, k-nearest neighbors, support vector machine, and decision tree are used in this study to detect the cyberbullying tweets and select the best performance model for cyberbullying prediction
Prevalence of PIK3CA mutations in Taiwanese patients with breast cancer: a retrospective next-generation sequencing database analysis
BackgroundBreast cancer is the most common cancer type that affects women. In hormone receptor–positive (HR+), human epidermal growth factor receptor 2−negative (HER2–) advanced breast cancer (ABC), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) is the most frequently mutated gene associated with poor prognosis. This study evaluated the frequency of PIK3CA mutations in the Taiwanese breast cancer population.MethodologyThis is a retrospective study; patient data were collected for 2 years from a next-generation sequencing database linked to electronic health records (EHRs). The primary endpoint was the regional prevalence of PIK3CA mutation. The secondary endpoints were to decipher the mutation types across breast cancer subtype, menopausal status, and time to treatment failure after everolimus (an mTOR inhibitor) or cyclin-dependent kinase 4/6 (CDK4/6) inhibitor treatment.ResultsPIK3CA mutations were identified in 278 of 728 patients (38%). PIK3CA mutations were reported in 43% of patients with HR−/HER2+ subtype and 42% of patients with HR+/HER2– postmenopausal status. A lower prevalence of PIK3CA mutations was observed in triple-negative (27%) and HR+/HER2– premenopausal patients (29%). The most common mutation was at exon 20 (H1047R mutation, 41.6%), followed by exon 9 (E545K mutation, 18.9% and E542K mutation, 10.3%). Among patients treated with CDK4/6 inhibitors, the median time to treatment failure was 12 months (95% CI: 7-21 months) in the PIK3CA mutation cohort and 16 months (95% CI: 11-23 months) in the PIK3CA wild-type cohort, whereas patients receiving an mTOR inhibitor reported a median time to treatment failure of 20.5 months (95% CI: 8-33 months) in the PIK3CA mutation cohort and 6 months (95% CI: 2-9 months) in the PIK3CA wild-type cohort.ConclusionA high frequency of PIK3CA mutations was detected in Taiwanese patients with breast cancer, which was consistent with previous studies. Early detection of PIK3CA mutations might influence therapeutic decisions, leading to better treatment outcomes
Women with endometriosis have higher comorbidities: Analysis of domestic data in Taiwan
AbstractEndometriosis, defined by the presence of viable extrauterine endometrial glands and stroma, can grow or bleed cyclically, and possesses characteristics including a destructive, invasive, and metastatic nature. Since endometriosis may result in pelvic inflammation, adhesion, chronic pain, and infertility, and can progress to biologically malignant tumors, it is a long-term major health issue in women of reproductive age. In this review, we analyze the Taiwan domestic research addressing associations between endometriosis and other diseases. Concerning malignant tumors, we identified four studies on the links between endometriosis and ovarian cancer, one on breast cancer, two on endometrial cancer, one on colorectal cancer, and one on other malignancies, as well as one on associations between endometriosis and irritable bowel syndrome, one on links with migraine headache, three on links with pelvic inflammatory diseases, four on links with infertility, four on links with obesity, four on links with chronic liver disease, four on links with rheumatoid arthritis, four on links with chronic renal disease, five on links with diabetes mellitus, and five on links with cardiovascular diseases (hypertension, hyperlipidemia, etc.). The data available to date support that women with endometriosis might be at risk of some chronic illnesses and certain malignancies, although we consider the evidence for some comorbidities to be of low quality, for example, the association between colon cancer and adenomyosis/endometriosis. We still believe that the risk of comorbidity might be higher in women with endometriosis than that we supposed before. More research is needed to determine whether women with endometriosis are really at risk of these comorbidities
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie
Production of He-4 and (4) in Pb-Pb collisions at root(NN)-N-S=2.76 TeV at the LHC
Results on the production of He-4 and (4) nuclei in Pb-Pb collisions at root(NN)-N-S = 2.76 TeV in the rapidity range vertical bar y vertical bar <1, using the ALICE detector, are presented in this paper. The rapidity densities corresponding to 0-10% central events are found to be dN/dy4(He) = (0.8 +/- 0.4 (stat) +/- 0.3 (syst)) x 10(-6) and dN/dy4 = (1.1 +/- 0.4 (stat) +/- 0.2 (syst)) x 10(-6), respectively. This is in agreement with the statistical thermal model expectation assuming the same chemical freeze-out temperature (T-chem = 156 MeV) as for light hadrons. The measured ratio of (4)/He-4 is 1.4 +/- 0.8 (stat) +/- 0.5 (syst). (C) 2018 Published by Elsevier B.V.Peer reviewe
Pseudorapidity and transverse-momentum distributions of charged particles in proton-proton collisions at root s=13 TeV
The pseudorapidity (eta) and transverse-momentum (p(T)) distributions of charged particles produced in proton-proton collisions are measured at the centre-of-mass energy root s = 13 TeV. The pseudorapidity distribution in vertical bar eta vertical bar <1.8 is reported for inelastic events and for events with at least one charged particle in vertical bar eta vertical bar <1. The pseudorapidity density of charged particles produced in the pseudorapidity region vertical bar eta vertical bar <0.5 is 5.31 +/- 0.18 and 6.46 +/- 0.19 for the two event classes, respectively. The transverse-momentum distribution of charged particles is measured in the range 0.15 <p(T) <20 GeV/c and vertical bar eta vertical bar <0.8 for events with at least one charged particle in vertical bar eta vertical bar <1. The evolution of the transverse momentum spectra of charged particles is also investigated as a function of event multiplicity. The results are compared with calculations from PYTHIA and EPOS Monte Carlo generators. (C) 2015 CERN for the benefit of the ALICE Collaboration. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Peer reviewe
Centrality evolution of the charged-particle pseudorapidity density over a broad pseudorapidity range in Pb-Pb collisions at root s(NN)=2.76TeV
Peer reviewe
The study on the impact of opening visitation for people from Mainland China area has on Taiwanese Economic Variables
本研究希望藉由討論自2002年元旦陸續開放的「大陸地區人士來台從事觀光許可辦法」中,針對已開放的第二、三類大陸人士來台觀光的人次為台灣經濟所帶來的影響力,作為評估將來全面開放後,能夠為台灣旅遊業及整體經濟面帶動多少正面效益。本文試圖結合多項時間序列方法檢測開放大陸人士來台觀光之人數對工業生產指數、匯率、股價波動及消費者物價指數等幾項相關性較高之總體經濟因素的長期均衡關係、短期領先落後關係及跨期衝擊之互動研究;其中所使用的時間序列方法包括:考慮數列是否具有定態性的單根檢定、數列長期均衡關係的共整合檢定以及數列間的因果關係檢定,最後作衝擊反應分析。而從結果分析看來,開放大陸人士來台觀光對台灣總體的經濟變數有著長期均衡的共移趨勢,而且互為因果關係,甚至股價指數與開放人數有著密切且顯著的短期衝擊反應。With the discussion on Taiwan’s economic impact resulting from the number of so-called the ‘second’ and ‘third’ categories of people from Mainland China visiting Taiwan, particularly as stipulated in “the regulations governing the approval of people from Mainland China area visiting Taiwan for tourist purposes” (effective since 2002), this study is to assess the positive effects on Taiwan’s tourism industry and the overall economic scope that has occurred due to this ‘Cross-Strait’ opening for Mainland Chinese tourists.
The highly relational factor of macroeconomics – the industrial production index, exchange rates, the stock market index and the consumer price indexes have been taken into consideration to examine the interrelationship of the long-run equilibrium and the short-term lead by using the time series method inclusive of unit root test ,co-integration test and Granger Causality, and in the end to conduct an analysis on inter-temporal impulses by using the impulse response function.
The results found that the number of people from Mainland China visiting Taiwan has a common moving trend of long-run equilibrium and causality with Taiwan macroeconomics factors and even has a short term impulse response with the stock market that is both close and significant.謝辭……………………….i
中文摘要………………… ii
英文摘要(Abstract)……iii
章節目錄…………………iv
表目錄……………………vi
圖目錄……………………vii
第一章 緒論 1
第一節 問題源起 1
第二節 研究目的 6
第三節 研究設計 8
第四節 論文結構與章節安排說明 14
第二章 文獻檢討 17
第三章 研究方法 21
第一節 單根檢定法 21
第二節 共整合檢定 25
第三節 GRANGER因果關係 29
第四節 衝擊反應函數 31
第五節 研究限制 33
第四章 研究分析及實證結果 34
第一節 單根檢定結果分析 34
第二節 共整合檢定結果分析 36
第三節 GRANGER因果關係檢定分析 38
第四節 衝擊反應結果分析 40
第五章 結論與建議 44
第一節 研究結果分析 44
第二節 研究結論 46
第三節 後續研究建議 47
參考文獻 49
附錄 5
Adjust cut-off values of immunohistochemistry models to predict risk of distant recurrence in invasive breast carcinoma patients
Background: Multigene assays are recommended for hormone receptor-positive invasive breast carcinoma to determine the risk of recurrence, but they are highly expensive. We investigated the prognostic values of immunohistochemistry (IHC)-based prognostic models as an alternative to multigene assays.
Methods: The risk categories estimated by the IHC-based prognostic models were correlated to those estimated by the multigene assays in 71 cases and the follow-up results in 642 consecutive cases of HER2− luminal-type early breast cancer. Cut-off values of IHC-based models were adjusted based on survival outcome to reveal maximum Harrell C index or based on the maximum positive likelihood ratio correlated to multigene assay.
Results: All investigated IHC-based models could predict the risk of distant recurrence, but their cut-off values required adjustment. Using distant recurrence-free survival (DRFS) to refine the cut-off values could improve the prognostic values. Adjusting the cut-off values using the results of multigene assays, the positive predictive values of an estimate of low risk or low recurrence score (≤ 21) were higher than 90%. On average, 23% of cases got different results of risk assessment after adjustment. Although cut-off values adjusted by multigene assay were not identical to those refined by survival, the adjusted values (17.1 and 23.8) and the refined values (17.5 and 24.5) of the best model (Magee Eq. 1) were close. Among all the evaluated models, Magee equation 2 was the only one without Ki67, and its prognostic values were the lowest. Using 20% as cut-off for Ki67 as suggested by St. Gallen consensus, we could confidently define luminal A cancer.
Conclusion: It is necessary to adjust the cut-off values of IHC-based prognostic models to fit the purpose. If the estimated risk is clearly high or low, it may be reasonable to omit multigene assays when cost is a consideration
Survival, health care resource utilization and expenditures of first-line treatments for multiple myeloma patients ineligible for transplant in Taiwan.
BackgroundWe aimed to provide real-world information on survival, health care resource utilization (HCRU), and expenditures related to various first lines of therapy (1LOTs) in newly diagnosed multiple myeloma (NDMM) patients who were transplant ineligible (TI).Patients and methodsFrom the Taiwan National Health Insurance Database (2008-2016), we identified 1,511 NDMM-TI patients who had received 1LOT since June 2012. We categorized 1LOT regimens into four groups: bortezomib (V)+thalidomide (T), V, T, and non-V/T. Patients' characteristics were collected. The overall survival (OS), event-free survival (EFS), frequencies of HCRU (hospitalization, visiting outpatient and emergency departments), and related expenditures within one year after commencement of the 1LOT were evaluated and compared.ResultsThe mean age of the included patients was 71.3 (SD 10.7) years, and 40.4% of patients had a CCI score ≥3. Most patients (747; 49.4%) were in the V+T group and, after adjusting for covariates, had a significantly longer OS (median, 22.2 months) and EFS (9.1 months) than those in the T group (12.6 and 4.5 months, respectively) and the non-V/T group (12.2 and 3.2 months, respectively), but they were mostly comparable with patients in the V group (23.8 and 6.6 months, respectively). Compared to those in the V+T group, patients in the T and non-V/T groups had 29% and 39% fewer outpatient visits and 15% and 24% lower total expenditure, respectively.ConclusionOur real-world data consolidate evidence for the effectiveness of bortezomib-containing regimens as the 1LOT in NDMM-TI patients at the expense of more outpatient visits and higher total costs
- …